
|Articles|October 1, 2012
Prostate cancer assay may help distinguish aggressive vs. indolent disease
A biopsy-based genomic assay that would discriminate between aggressive prostate cancer and indolent disease to guide treatment decisions is under development.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Practical uses of AI across the urologic care continuum
2
Study progresses of nogapendekin alfa inbakicept for BCG-naïve NMIBC
3
The UroOnc Minute: Diet and Prostate Cancer, with Stephen J. Freedland, MD
4
Walter Hsiang, MD, discusses insurance-related barriers to kidney stone care
5



















